Myricx Bio, a pioneering UK biotech company, is thrilled to announce the successful completion of a funding round that has raised an impressive £90 million. This significant investment marks a key milestone in our journey towards revolutionizing cancer treatment through the discovery and development of a groundbreaking class of selective cytotoxic payloads for antibody-drug conjugates (ADCs). Our innovative approach centers on harnessing inhibitors of N-myristoyltransferases (NMT) to create targeted therapies that promise to enhance the efficacy of ADCs while minimizing off-target effects. The funds raised will be instrumental in accelerating our research and development initiatives, allowing us to expand our pipeline of promising candidates and bring new hope to patients battling various forms of cancer. With this backing, Myricx Bio is poised to advance its lead programs toward clinical trials and establish collaborations that will propel our transformative science into the clinic. We are grateful for the confidence our investors have shown in our vision and are eager to demonstrate the potential of our novel payloads in addressing urgent unmet medical needs. As we move forward, Myricx Bio remains firmly committed to pushing the boundaries of what's possible in cancer therapeutics and improving the lives of patients worldwide.










.png&w=3840&q=75)